This page compares ibogaine and psilocybin as potential treatments for depression, covering mechanism of action, clinical evidence, safety, cost, and access. Both substances have attracted significant research interest, yet they differ substantially in risk profile, legal status, and the populations most likely to benefit.

At a Glance

Criterion Ibogaine Psilocybin
Primary Mechanism Multi-receptor: NMDA antagonism, opioid receptor modulation, serotonin reuptake inhibition, sigma-2 agonism 5-HT2A receptor agonism; neuroplasticity via BDNF upregulation
Evidence Level Early-phase; observational studies, small open-label trials Phase 2 randomized controlled trials; FDA Breakthrough Therapy designation
Session Duration 18–36 hours 4–8 hours
US Legal Status Schedule I (federal); decriminalized in some localities Schedule I (federal); legal for therapeutic use in Oregon & Colorado
Access Licensed clinics in Mexico, Costa Rica, Netherlands, Canada; very limited domestically Licensed service centers in Oregon; clinical trials in multiple US cities
Typical Cost $5,000–$12,000+ per treatment $1,500–$3,500 per session (Oregon); trial access may be free
Key Risks Cardiac arrhythmia, QT prolongation, fatalities reported; contraindicated with many medications Anxiety, transient psychological distress; rare adverse cardiac events; low physical toxicity
May Be Best For Treatment-resistant depression with co-occurring opioid or stimulant use disorder Major depressive disorder, treatment-resistant depression without significant cardiac risk

Mechanism of Action

Ibogaine and psilocybin both produce lasting antidepressant effects through a single or limited number of sessions, but they arrive at that outcome through fundamentally different pharmacology.

Ibogaine is a naturally occurring alkaloid from the Central African shrub Tabernanthe iboga. Its antidepressant and anti-addictive properties are thought to involve several simultaneous pathways: antagonism of NMDA glutamate receptors (similar in some respects to ketamine), inhibition of the serotonin transporter (SERT), agonism at kappa- and sigma-2 opioid receptors, and interaction with nicotinic acetylcholine receptors. Its primary active metabolite, noribogaine, has a much longer half-life and contributes to sustained effects, including serotonin reuptake inhibition lasting days to weeks. This complex, polypharmacological profile is believed to underlie both its intensity and its breadth of action across multiple psychiatric and substance use conditions.

Psilocybin is metabolized to psilocin, which binds with high affinity to serotonin 5-HT2A receptors — particularly dense in the prefrontal cortex — inducing large-scale changes in default mode network (DMN) activity. Reduced DMN connectivity is associated with the dissolution of rigid, ruminative thought patterns linked to depression. Psilocybin also promotes synaptogenesis and upregulation of brain-derived neurotrophic factor (BDNF), suggesting a neuroplasticity mechanism that may explain effects persisting well beyond the drug's pharmacological half-life. Its mechanism is considerably more targeted than ibogaine's, which contributes to its comparatively more predictable safety profile.

Clinical Evidence

Psilocybin currently has a substantially stronger evidence base for depression specifically. Landmark randomized controlled trials — including a 2021 New England Journal of Medicine study by Carhart-Harris et al. comparing psilocybin to escitalopram in major depressive disorder, and COMPASS Pathways' Phase 2b trial of COMP360 (synthetic psilocybin) in treatment-resistant depression — have demonstrated significant reductions in depression scores with acceptable tolerability. Psilocybin received FDA Breakthrough Therapy designation for treatment-resistant depression and major depressive disorder, accelerating its regulatory pathway. Multiple Phase 3 trials are currently underway.

Ibogaine evidence for depression specifically is thinner, though growing. Most published data come from observational studies and open-label trials focused on opioid use disorder, with depression as a secondary outcome. A widely cited 2023 Stanford study (Marton et al.) examined ibogaine with magnesium supplementation in veterans with traumatic brain injury and found large reductions in PTSD, anxiety, and depression scores — though this was a non-randomized study in a specific population. Earlier naturalistic studies by Noller, Brown, and colleagues in New Zealand also documented meaningful antidepressant effects. No Phase 2 or Phase 3 randomized controlled trials for depression as a primary indication are yet complete. The evidence gap is significant and makes direct comparison with psilocybin difficult.

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision and pre-treatment cardiac screening required.

Safety Profile

Ibogaine carries the more serious physical safety concerns of the two substances. It prolongs the cardiac QT interval, which can precipitate potentially fatal ventricular arrhythmias — particularly torsades de pointes. Fatalities associated with ibogaine administration have been documented in the literature, most frequently in individuals with pre-existing cardiac conditions or in settings lacking adequate screening. Ibogaine is contraindicated with a wide range of medications, including SSRIs, antipsychotics, stimulants, and many opioids, as well as in people with a personal or family history of certain cardiac conditions. Pre-treatment ECG, electrolyte panel, and full medication review are considered minimum safety requirements. The required fasting period, session length of up to 36 hours, and post-experience monitoring add further logistical demands. Psychological risks include a powerful and sometimes difficult visionary experience that can be destabilizing without proper preparation and integration support.

Psilocybin has a substantially lower physical toxicity profile. It is not cardiotoxic at therapeutic doses, carries no meaningful risk of organ damage, and is not considered physiologically addictive. The primary safety concerns are psychological: acute anxiety, panic, or distressing experiences ("difficult trips") that, in uncontrolled settings or vulnerable individuals, may exacerbate psychiatric symptoms. Clinical trial protocols use psychological screening, trained facilitators, and structured post-session integration to mitigate these risks. Psilocybin is contraindicated or requires caution in people with a personal or family history of schizophrenia or bipolar I disorder, and at high doses can cause transient increases in blood pressure. Deaths directly attributable to psilocybin alone in controlled settings are not documented in the literature.

Cost and Access

Ibogaine is not legally available in the United States at the federal level, and access requires traveling to a licensed clinic abroad — most commonly in Mexico, Costa Rica, the Netherlands, or Canada. Treatment packages at reputable medical clinics typically cost between $5,000 and $12,000 or more, which includes pre-screening, the session itself, and a period of residential aftercare. Travel costs add to this figure. Quality and medical oversight vary considerably across providers, making due diligence in clinic selection critical. Some US veterans organizations have facilitated access to vetted international providers, and domestic decriminalization in cities like Oakland and Seattle does not create a legal pathway for clinical administration.

Psilocybin access is expanding but remains geographically limited domestically. Oregon's Measure 109 framework, which became operational in 2023, allows licensed service centers to administer psilocybin to adults without a diagnosis requirement. Colorado's Proposition 122, which passed in 2022, is rolling out a similar supervised-use framework. Session costs in Oregon currently range from roughly $1,500 to $3,500, not including facilitator preparation or integration sessions. Participation in clinical trials — including ongoing Phase 3 studies — may provide access at no cost, though eligibility criteria apply. Internationally, Australia became the first country to permit TGA-authorized psychiatrists to prescribe psilocybin for treatment-resistant depression, opening another avenue for those who can access it.

Who Each Treatment May Suit

Ibogaine may be of particular interest to individuals with treatment-resistant depression who also have a co-occurring opioid, alcohol, or stimulant use disorder — a population in which its dual mechanism may offer advantages that psilocybin has not yet demonstrated as clearly. It has attracted attention for veterans and others with co-occurring PTSD and depression, as seen in recent research. However, anyone with cardiac risk factors, a complex medication regimen, or limited access to internationally traveled medical care faces meaningful barriers. Its appropriateness requires rigorous medical screening that rules out a wide range of contraindications.

Psilocybin may be better suited to individuals with major depressive disorder or treatment-resistant depression who do not have the cardiac contraindications that disqualify ibogaine, who prefer a shorter session, or who want access to a supervised domestic experience in Oregon or Colorado. Those who have tried and failed multiple antidepressant medications — the core population studied in Phase 2 trials — represent the most evidence-supported target group currently. Individuals with a personal or family history of psychotic disorders should exercise caution and consult a psychiatrist before pursuing either substance.

Key Difference

The most clinically significant difference between ibogaine and psilocybin for depression is not their mechanism or even their efficacy — both show promising but still-developing evidence — but their risk-to-access ratio. Psilocybin has a more established safety record in clinical settings, is supported by more rigorous randomized trial data specifically for depressive disorders, and is increasingly accessible through regulated domestic frameworks. Ibogaine offers a broader pharmacological reach that may serve populations with co-occurring addiction, but it carries a serious cardiac risk profile that demands a level of pre-treatment medical infrastructure most outpatient settings cannot provide, and its evidence base for depression as a standalone indication remains observational. Neither substance is yet an approved pharmaceutical treatment for depression in the United States, and both carry meaningful psychological and logistical considerations that distinguish them from standard-of-care antidepressants.

Frequently Asked Questions

Both have been associated with antidepressant effects persisting weeks to months after a single administration in research settings. Ibogaine is typically administered as a single flood dose, though booster sessions are sometimes used. Psilocybin clinical protocols have used one to three sessions. Durability of effects varies considerably between individuals, and neither should be considered a permanent cure based on current evidence. Integration therapy following either experience is widely considered important for sustaining benefit.
In terms of physical toxicity, psilocybin has a substantially more favorable safety profile than ibogaine. Psilocybin is not cardiotoxic and deaths directly attributable to it in supervised settings are not documented in the literature. Ibogaine carries documented risk of fatal cardiac arrhythmia, particularly in individuals with QT interval abnormalities or those taking contraindicated medications. Both substances carry psychological risks and require careful screening and professional oversight. Calling either categorically "safe" would be inaccurate — context, individual health status, and setting matter enormously for both.
This is one of the most clinically important questions for both substances. SSRIs and SNRIs significantly blunt the effects of psilocybin and may need to be tapered under physician supervision before treatment — a process that itself carries risks, including discontinuation symptoms and return of depression. For ibogaine, the contraindication is more serious: SSRIs, certain antipsychotics, stimulants, and many other medications substantially increase cardiac risk. Continuing these medications alongside ibogaine is generally considered dangerous. Any medication changes should be managed by a qualified physician familiar with these interactions; never discontinue psychiatric medications without professional guidance.
Currently, no published head-to-head randomized controlled trial compares ibogaine and psilocybin directly for depression. The two substances have been studied in different populations, using different outcome measures and trial designs, making indirect comparisons difficult. Psilocybin has more rigorous RCT data specifically for depressive disorders. Ibogaine's depression data comes largely from observational studies or as secondary outcomes in addiction-focused trials. Meaningful direct comparison awaits better-matched study designs.
The available evidence does not allow a definitive answer. Psilocybin studies have documented sustained antidepressant effects at 3-, 6-, and in some cases 12-month follow-ups. Ibogaine's noribogaine metabolite has a half-life of several days and may contribute to extended effects; observational reports of sustained mood improvement lasting months have been published. However, methodological differences between studies — different populations, outcome tools, and follow-up periods — make duration comparisons unreliable. Individual response is highly variable for both.
Neither treatment is currently covered by health insurance in the United States. Both remain Schedule I federally, and no FDA-approved indication for either substance in depression exists yet. Out-of-pocket costs are substantial for both, though ibogaine — requiring international travel and residential care — typically has higher total costs. Some clinical trials for psilocybin cover participant costs. As regulatory pathways advance, insurance coverage may evolve, but no timeline is certain.
Ibogaine produces an intense, often dreamlike visionary state lasting 4–8 hours, followed by a prolonged period of introspective wakefulness that can extend to 24–36 hours total. Participants frequently report vivid autobiographical imagery, confrontation of past experiences, and a sense of deep psychological processing. Physical effects include ataxia and sensitivity to light and sound. Psilocybin sessions, typically 4–8 hours, involve altered perception, emotional amplification, ego dissolution at higher doses, and often profound feelings of connectedness or meaning. Both experiences can be challenging — even distressing — for some individuals, which is why psychological preparation and experienced facilitation are considered essential in responsible clinical protocols.
Yes, both carry this risk in vulnerable individuals or unsupported settings. Psilocybin can trigger or unmask psychotic episodes in those predisposed to schizophrenia or bipolar I disorder, and difficult experiences without integration support have been associated with persistent psychological distress (sometimes called HPPD or hallucinogen persisting perception disorder, though this is relatively rare). Ibogaine's intense and uncontrollable visionary state can be destabilizing for individuals with certain trauma histories or without adequate psychological preparation. Both substances require pre-screening for psychiatric history, and clinical protocols include preparation and integration support specifically to reduce these risks.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.